Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunovantIMVT +0.36%29 3-Year FCF Growth Rate is -13.40% as of Jun. 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,108 Biotechnology companies, Immunovant ranks worse than 83.39% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -13.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -22.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Immunovant was -7.40% per year. The lowest was -36.80% per year. And the median was -15.55% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Immunovant 3-Year FCF Growth Rate Related Terms
IMVT vs IBRX, TGTX, PCVX: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Immunovant's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovant 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunovant's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Immunovant's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -13.40% mean?
Immunovant (IMVT) has a 3-Year FCF Growth Rate of -13.40% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Immunovant and its competitors. According to the industry distribution chart, Immunovant ranks #924 out of 1108 companies in the Biotechnology industry, placing it in the top 83.4%.
Is Immunovant's 3-Year FCF Growth Rate too high?
Immunovant's current 3-Year FCF Growth Rate is -13.40%. Based on the distribution chart, Immunovant ranks #924 out of 1108 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's 3-Year FCF Growth Rate compare to IBRX and TGTX?
According to the Biotechnology industry distribution chart, Immunovant ranks #924 out of 1108 companies for 3-Year FCF Growth Rate. This places Immunovant in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 19.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.35, based on 1,108 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Immunovant and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovant's current 3-Year FCF Growth Rate is -13.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current 3-Year FCF Growth Rate of -13.40%. The current 3-Year FCF Growth Rate is -13.40%. Immunovant's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Immunovant (IMVT), the current 3-Year FCF Growth Rate is -13.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score
Get the complete analysis for IMVT
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMVT has been successfully added to your 
